See more : Tactical Resources Corp. (RARE.CN) Income Statement Analysis – Financial Results
Complete financial analysis of DexCom, Inc. (DXCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DexCom, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Shinfox Energy Co., Ltd. (6806.TW) Income Statement Analysis – Financial Results
- TTEC Holdings, Inc. (TTEC) Income Statement Analysis – Financial Results
- Crumbs Bake Shop, Inc. (CRMBQ) Income Statement Analysis – Financial Results
- SKM Egg Products Export (India) Limited (SKMEGGPROD.NS) Income Statement Analysis – Financial Results
- Unibail-Rodamco-Westfield SE (URW.AS) Income Statement Analysis – Financial Results
DexCom, Inc. (DXCM)
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.62B | 2.91B | 2.45B | 1.93B | 1.48B | 1.03B | 718.50M | 573.30M | 402.00M | 259.20M | 160.00M | 99.90M | 76.27M | 48.63M | 29.69M | 9.84M | 4.63M | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33B | 1.03B | 768.00M | 646.60M | 544.50M | 367.70M | 226.40M | 194.90M | 123.60M | 82.90M | 59.90M | 53.30M | 40.42M | 30.19M | 26.03M | 15.37M | 12.74M | 10.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.29B | 1.88B | 1.68B | 1.28B | 931.50M | 663.90M | 492.10M | 378.40M | 278.40M | 176.30M | 100.10M | 46.60M | 35.84M | 18.44M | 3.66M | -5.53M | -8.11M | -8.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 63.19% | 64.72% | 68.63% | 66.44% | 63.11% | 64.36% | 68.49% | 66.00% | 69.25% | 68.02% | 62.56% | 46.65% | 47.00% | 37.92% | 12.33% | -56.20% | -175.25% | -405.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 505.80M | 484.20M | 604.20M | 359.90M | 273.50M | 417.40M | 185.40M | 156.10M | 137.50M | 69.40M | 44.80M | 39.50M | 30.75M | 23.23M | 14.29M | 19.63M | 16.13M | 19.42M | 26.77M | 12.47M | 8.93M | 6.31M | 5.04M | 2.90M |
| General & Administrative | 1.00B | 867.20M | 684.10M | 544.20M | 482.60M | 408.80M | 327.30M | 274.30M | 194.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 180.80M | 133.00M | 126.40M | 76.50M | 33.10M | 24.00M | 21.90M | 11.90M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 325.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.19B | 1.00B | 810.50M | 620.70M | 515.70M | 432.80M | 349.20M | 286.20M | 198.00M | 128.40M | 84.20M | 62.80M | 49.94M | 40.51M | 35.20M | 27.67M | 22.44M | 21.11M | 5.66M | 1.60M | 1.25M | 0.00 | 1.69M | 1.11M |
| Other Expenses | 0.00 | 7.50M | -1.70M | 0.00 | 0.00 | 0.00 | 3.40M | -700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.69B | 1.49B | 1.41B | 980.60M | 789.20M | 850.20M | 534.60M | 442.30M | 335.50M | 197.80M | 129.00M | 102.30M | 80.69M | 63.73M | 49.49M | 47.30M | 38.57M | 40.53M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Cost & Expenses | 3.02B | 2.52B | 2.18B | 1.63B | 1.33B | 1.22B | 761.00M | 637.20M | 459.10M | 280.70M | 188.90M | 155.60M | 121.11M | 93.92M | 75.53M | 62.67M | 51.30M | 51.49M | 32.43M | 14.07M | 10.18M | 6.31M | 6.72M | 4.01M |
| Interest Income | 135.00M | 18.00M | 1.70M | 16.10M | 26.40M | 2.40M | 3.30M | 400.00K | 0.00 | 0.00 | 0.00 | 100.00K | 107.00K | 95.00K | 354.00K | 1.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.30M | 18.60M | 102.00M | 84.70M | 60.30M | 22.70M | 12.80M | 700.00K | 400.00K | 800.00K | 900.00K | 200.00K | 11.00K | 1.55M | 8.05M | 7.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 186.00M | 155.90M | 101.90M | 67.10M | 48.70M | 29.10M | 16.10M | 15.00M | 10.80M | 8.40M | 7.00M | 6.60M | 3.76M | 2.44M | 2.37M | 3.58M | 3.33M | 2.70M | 1.07M | 935.49K | 353.55K | 0.00 | 0.00 | 0.00 |
| EBITDA | 916.70M | 565.30M | 377.50M | 376.80M | 213.20M | -74.70M | -19.70M | -49.20M | -46.30M | -13.10M | -21.90M | -49.00M | -40.98M | -51.19M | -43.11M | -49.79M | -43.34M | -46.62M | -29.70M | -13.13M | -9.83M | -6.31M | -6.72M | -4.01M |
| EBITDA Ratio | 25.31% | 14.33% | 11.33% | 19.86% | 11.14% | -10.06% | -4.98% | -11.20% | -14.20% | -8.29% | -13.69% | -49.05% | -53.87% | -70.79% | -146.36% | -500.90% | -936.76% | -2,148.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 597.70M | 391.20M | 175.40M | 299.50M | 142.30M | -186.30M | -42.50M | -63.90M | -57.10M | -21.50M | -28.90M | -55.70M | -44.84M | -45.29M | -45.83M | -52.83M | -46.68M | -49.32M | -32.43M | -14.07M | -10.18M | -6.31M | -6.72M | -4.01M |
| Operating Income Ratio | 16.50% | 13.44% | 7.16% | 15.54% | 9.64% | -18.06% | -5.92% | -11.15% | -14.20% | -8.29% | -18.06% | -55.76% | -58.80% | -93.13% | -154.36% | -536.97% | -1,008.77% | -2,273.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 112.70M | -400.00K | -9.00M | -74.50M | -38.10M | 59.80M | -6.10M | -1.00M | -400.00K | -800.00K | -900.00K | -100.00K | 97.00K | -9.88M | -7.69M | -2.36M | 798.00K | 2.72M | -30.86B | 120.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 710.40M | 390.80M | 173.90M | 225.00M | 104.20M | -126.50M | -48.60M | -64.90M | -57.50M | -22.30M | -29.80M | -55.80M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 19.61% | 13.43% | 7.10% | 11.68% | 7.06% | -12.26% | -6.76% | -11.32% | -14.30% | -8.60% | -18.63% | -55.86% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 168.90M | 49.60M | 19.20M | -268.60M | 3.10M | 600.00K | 1.60M | 700.00K | 100.00K | 100.00K | 0.00 | -1.30M | -97.00K | 9.88M | 0.00 | 2.36M | 0.00 | 253.00 | -30.86B | -120.65K | -270.00K | 7.71M | 6.27M | 3.97M |
| Net Income | 541.50M | 341.20M | 154.70M | 493.60M | 101.10M | -127.10M | -50.20M | -65.60M | -57.60M | -22.40M | -29.80M | -54.50M | -44.75M | -55.17M | -53.52M | -55.18M | -45.88M | -46.60M | -30.77M | -13.95M | -9.91M | -7.71M | -6.27M | -3.97M |
| Net Income Ratio | 14.95% | 11.73% | 6.32% | 25.62% | 6.85% | -12.32% | -6.99% | -11.44% | -14.33% | -8.64% | -18.63% | -54.55% | -58.67% | -113.45% | -180.26% | -560.93% | -991.53% | -2,147.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.44 | 0.88 | 0.40 | 1.31 | 0.28 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| EPS Diluted | 1.30 | 0.80 | 0.36 | 1.27 | 0.27 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 | -0.10 | -0.20 | -0.17 | -0.24 | -0.30 | -0.47 | -0.41 | -0.43 | -0.41 | -1.53 | -1.14 | -0.94 | -0.83 | -0.57 |
| Weighted Avg Shares Out | 386.00M | 389.40M | 386.90M | 377.60M | 364.40M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
| Weighted Avg Shares Out (Dil) | 425.50M | 427.50M | 428.80M | 390.00M | 369.20M | 352.80M | 345.20M | 334.40M | 319.20M | 300.80M | 284.40M | 274.80M | 262.40M | 227.60M | 177.39M | 117.95M | 113.25M | 108.94M | 75.78M | 9.14M | 8.68M | 8.18M | 7.59M | 6.91M |
DexCom Growing Into Its Valuation, But Still No Bargain
DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed disappointing 2% revenue growth and a 26% decline in operating...
DexCom, Inc. (DXCM) Q3 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q3 2024 Earnings Call Transcript October 24, 2024 4:30 PM ET Company Participants Sean Christensen - VP, Finance and IR Kevin Sayer - President and CEO Jereme Sylvain - CFO Conference Call Participants Danielle Antalffy -...
DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.50 per share a year ago.
Dexcom shares fall on slow revenue growth
Dexcom shares fell on Thursday after the company released third-quarter results that beat expectations but showed slow revenue growth. The company's revenue increased 2% from $975 million a year earlier, according to a release.
Dexcom beats estimates for third-quarter sales, reiterates annual forecast
Medical device maker Dexcom beat Wall Street estimates for third-quarter revenue on Thursday, helped by resilient demand for its continuous glucose monitors for diabetes patients.
Dexcom Reports Third Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year...
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on behalf of long-term stockholders following a class action complaint that...
Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?
DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Source: https://incomestatements.info
Category: Stock Reports